Business Wire

NV-WEJO-GROUP

4.1.2022 22:32:08 CET | Business Wire | Press release

Share
Wejo Announces Wejo Neural Edge Processing Platform Streamlining Connected Vehicle Data and Driving Autonomous Vehicle Reality Forward

Wejo Group Limited (NASDAQ: WEJO), a global leader in cloud and software analytics generated from AV, EV and connected vehicle data (CVD), today announced it is developing a breakthrough Wejo Neural EdgeTM platform that will enable intelligent handling of data from vehicles at scale, while providing incredible insights that protect privacy and empower automotive innovation. In partnership with Microsoft, Wejo will make the announcement virtually from the Microsoft Partners Pavilion at the Consumer Electronics Show in Las Vegas.

With so much rich data coming from vehicles today, latency and data storage costs are potential obstacles in harnessing and scaling the power of real-time vehicle communications - both with other vehicles and the infrastructure that is set to power Smart Cities. Leveraging our strategic partnership with Microsoft Azure and powered by Wejo’s ADEPT platform, Wejo Neural EdgeTM optimizes how this data is managed within the vehicle, further processes it at the Edge and ultimately communicates to the cloud. This process will not only reduce data overload and maximize data insights but will reduce costs for automotive manufacturers and improve manufacturing of the vehicle to provide a better driving experience – supporting safer vehicles, enabling further advancements in EV and autonomous mobility, and reducing congestion and emissions.

“When I started Wejo in 2014, I knew that the proliferation of new mobility technology would drive data to a tipping point. And we are at that point today,” said Richard Barlow, Founder & CEO, Wejo. “With today’s vehicles producing approximately 25 gigabytes of data per hour, and as vehicle technology advances adding more sensors, data filtering and neural edge processing technology is essential to reduce this overload and drive the industry forward. Partnering with Microsoft and Palantir has positioned us to address this problem today, and to look ahead at the benefits of Wejo Neural EdgeTM as a driver in the growth of autonomous mobility. “

Wejo Neural EdgeTM will filter and analyze vast amounts of AV, EV and CV data before transmitting only the essential information to the cloud. This is made possible by utilizing in-car edge processing that Wejo is developing to filter only useful and valuable CVD before it is transmitted to the cloud. The embedded software technology in combination with Microsoft Azure cloud computing platform will enable Wejo Neural EdgeTM to power automotive innovation by:

  • Reducing network and storage costs for the auto manufacturers by optimising the data coming from the vehicle. Leveraging embedded software within the vehicle chipset, Wejo Neural EdgeTM is designed to intelligently choose and prioritize the data to be sent from the vehicle to the cloud.
  • Utilizing machine learning algorithms to reconstruct vehicle journey and event data, Wejo Neural EdgeTM can take 20% of the data from autonomous, electric, and other connected vehicles and reconstruct it to represent 100% of the data, without any loss in data fidelity or integrity. The positive environmental impact is significant, as less data requires less storage which in turn reduces power consumption.
  • Enabling Vehicle to Vehicle (V2V) and Vehicle to Infrastructure (V2X) communications. Wejo Neural EdgeTM enables the standardisation and centralisation of the data that comes from autonomous, electric and connected vehicles. Not only does this provide a key building block for communication in near real time, but it also supports communication with infrastructure services such as road signs, traffic lights and parking lots, so vehicles can easily anticipate the road ahead and optimise mobility experiences.
  • Delivering a digital twin of the vehicle and cities to reshape how we view the entire product and service ecosystem related to mobility. In a simulation environment, a digital twin of the US can be constructed to simulate how vehicles in different cities need to respond and navigate without having to outlay massive infrastructure costs of physical hardware or vehicles to be able to relearn how a vehicle should behave as an AV or EV, in the Smart City, etc.

“At Wejo, we believe that digital twins will reshape everything from road safety, to insurance, advertising, after-sales and more,” said David Burns, Chief Technology Officer, Wejo. “With Wejo Neural Edge we can look at what a CV is doing a kilometer away, and then alter and change the driver experience of an AV based on the information that is coming from down the road.”

As more auto manufacturers work to harness their vehicle data, Wejo Neural EdgeTM and Wejo’s common data model will enable different manufacturer makes and models to speak the same data language, a key component supporting vehicle to vehicle communication and vehicle communications with infrastructure and services. Wejo’s continued partnership with Palantir furthers how this model can adeptly address the problems of today and inform decisions for tomorrow.

“Our ongoing partnership with Wejo is focused on the most complex and critical challenges facing the future of mobility” says Shyam Sankar, Chief Operating Officer of Palantir Technologies. “What Wejo is building atop Palantir Foundry, including their cutting-edge neural edge technology, is a testament to the depth of their vision, speed of execution, and power of combining our technologies.”

Further details about the availability of the Wejo Neural Edge Processing platform will come at a future date.

About Wejo

Wejo (NASDAQ: WEJO) is a global leader in connected vehicle data, revolutionising the way we live, work and travel by transforming and interpreting historic and real-time vehicle data. The company enables smarter mobility by organising trillions of data points from 11.9 million vehicles and more than 60 billion journeys globally, across multiple brands, makes and models, and then standardising and enhancing those streams of data on a vast scale. Wejo partners with ethical, like-minded companies and organisations to turn that data into insights that unlock value for consumers. With the most comprehensive and trusted data, information and intelligence, Wejo is creating a smarter, safer, more sustainable world for all. Founded in 2014, Wejo employs more than 250 people and has offices in Manchester in the UK and in regions where Wejo does business around the world. For more information, visit: www.wejo.com .

About Palantir

Palantir Technologies Inc. builds and deploys operating systems for the modern enterprise. Additional information is available at https://www.palantir.com .

Who dares, wins.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this release, including statements regarding the Company’s future operating results and financial position, business strategy and plans, objectives of management for future operations are forward-looking statements. These statements are based on the Company’s current expectations, assumptions, estimates and projections. These statements involve known and unknown risks, uncertainties and other important factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements are based on management's current expectations and assumptions regarding the Company’s business, the economy and other future conditions.

Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, without limitation, those factors described in the Company’s filings with the Securities and Exchange Commission.

These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially, and potentially adversely, from those expressed or implied in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: (i) the impact of the COVID-19 pandemic on the Company’s business; (ii) the inability to obtain or maintain the listing of the Company’s common shares on the Nasdaq Stock Market following the business combination; (iii) the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth profitably, and retain its key employees; (iv) changes in applicable laws or regulations; (v) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors, and (vi) the company’s ability to maintain effective internal control over financial reporting and disclosure controls and procedures. The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in Wejo’s Form 10-Q for the period ended September 30, 2021 and Wejo’s most recent filings with the SEC. All readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based, except as required by law.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye